Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrelizumab + albumin paclitaxel + apatinib with or without Fuzi Lizhong Pill in unresectable/metastatic pancreatic cancer
ChiCTR2200058126Phase 2Not yet recruiting
- Sponsor
- Second People's Hospital of Anhui Province
- Start
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, nab-paclitaxel, Rivoceranib and Fuzi Lizhong Pill in pancreatic cancer (PC), sponsored by Second People's Hospital of Anhui Province. Primary endpoint: objective remission rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
camrelizumabnab-paclitaxelRivoceranibFuzi Lizhong Pill
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2200058126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058126.